Physician profile
Nicole Pearson
NPI 1194726430
$2,467.83
in general payments reported to CMS, 2019-2025
25 companies · $683 in 2025
The $683 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $225 · 2021: $324 · 2022: $54.63 · 2023: $158 · 2024: $629 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $591.61 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $321.59 | 2023-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $261.40 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $171.90 | 2019-2024 | Bexsero, Rotarix |
| Adlon Therapeutics L.P. | $131.58 | 2020-2021 | |
| Cranial Technologies, INC | $129.71 | 2019-2025 | Doc Band |
| Tris Pharma INC | $121.68 | 2019-2025 | Quillivant |
| Ironshore Pharmaceuticals INC. | $115.36 | 2019-2024 | |
| Abbvie INC. | $115.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.45 | 2019-2021 | |
| Neos Therapeutics, LP | $73.31 | 2019 | |
| Vertical Pharmaceuticals, LLC | $42.81 | 2019 | |
| Lnhc, INC | $37.90 | 2025 | Zelsuvmi |
| Shire North American Group INC | $34.31 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.43 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.38 | 2019 | |
| Tempus Ai, INC | $27.19 | 2024 | |
| Qiagen, LLC | $26.99 | 2025 | |
| Rhodes Pharmaceuticals L.P. | $20.15 | 2019 | |
| Kaleo, INC. | $20.00 | 2021 | |
| Phadia US INC. | $19.39 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.68 | 2025 | Zoryve |
| Grifols USA, LLC | $16.96 | 2024 | Prolastin-C Liquid |
| Pfizer INC. | $16.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.